Navigation Links
ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Date:12/10/2009

hase II, randomized, double-blind, sham controlled trial of microplasmin intravitreal injection (125 μg) for the treatment of focal vitreomacular adhesion (separation of the vitreous from the retina) in patients with exudative (wet) AMD. The trial will enroll approximately 100 patients at up to 20 centers across five European countries. The primary endpoint of the trial is non-surgical resolution of vitreomacular adhesion, defined as the separation of the vitreous from the retina by 28 days. This will be assessed by the Central Reading Center based on optical coherence tomography (OCT) images. Additional measures of efficacy and safety will also be assessed over a one year follow-up period.

Microplasmin has the potential to transform the treatment of a number of other important back of the eye diseases as well as AMD. Microplasmin is currently being evaluated in a Phase III program of approximately 640 patients, for the non-surgical treatment of focal vitreomacular adhesion.

Dr. Patrik De Haes, CEO of ThromboGenics commenting on the announcement said, "We are very pleased to announce the start of a Phase II trial of microplasmin in such a significant condition as AMD. It is increasingly clear that vitreomacular adhesion plays a key role in AMD sufferers with a poorer prognosis. Microplasmin's potential to cleave the vitreous from the retina could therefore represent an important advance in the treatment of this patient group. The start of this trial underlines the potential broad applicability of our lead product, and is another important step as we create a profitable integrated company focused on cutting edge ophthalmic medicines."

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III cl
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
2. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
3. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
4. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
7. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
8. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
9. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
10. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
11. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... N.J. , April 28, 2015 As ... Stryker Orthopaedics, is kicking off tournament week by heading ... second consecutive year appearing at the tournament, Stryker continues ... about the importance of joint health and mobility. As ... , Stryker is bringing new features to enhance ...
(Date:4/28/2015)... April 28, 2015   HX360 today ... of the inaugural HX360 Innovation Challenge ... improved patient experience in hospital and health system ... original field of eighty-three entries, with the four ... panel during the HX360 Innovation Challenge program at ...
(Date:4/28/2015)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... I am very excited to announce that we ... clinical trial for oral insulin (ORMD-0801) and the treatment of ... in the coming weeks. This clinical trial will be our largest ... milestone for the company, literally putting us in a different ...
Breaking Medicine Technology:The Stryker Mobility Zone Heads to Insperity Invitational for Second Consecutive Year 2The Stryker Mobility Zone Heads to Insperity Invitational for Second Consecutive Year 3The Stryker Mobility Zone Heads to Insperity Invitational for Second Consecutive Year 4Ginger.io And WiserCare Named Winners Of The HX360 Innovation Challenge 2Ginger.io And WiserCare Named Winners Of The HX360 Innovation Challenge 3Oramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter 2Oramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter 3
... Aug. 2 Cytokine PharmaSciences,Inc. (CPSI) today ... inhibitors showed oral efficacy in animal models. ... it is advancing one of these compounds,into ... or MIF, is linked to many,conditions, including ...
... ARBOR, Mich., Aug. 3 Far more of today,s,heart attack ... clogged heart arteries than even a,decade ago, a new study ... from this urgent treatment,-- which is known to save lives ... it at all, the study shows. And the chance ...
Cached Medicine Technology:Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors 2Many Heart Attack Patients Don't Get Best Emergency Treatment 2Many Heart Attack Patients Don't Get Best Emergency Treatment 3Many Heart Attack Patients Don't Get Best Emergency Treatment 4
(Date:4/28/2015)... 28, 2015 OsteoRemedies®, LLC, Memphis, ... two-stage revision of infected hip and knee arthroplasty. ... as a pre-formed, pre-loaded spacer with Gentamicin Antibiotics, ... joint space. Combined with a consistent process ... spacer is approved for temporary use for up ...
(Date:4/28/2015)... CA (PRWEB) April 28, 2015 Once considered ... Grow Lights have taken the industry by storm with perfectly ... to use unit. , More than half of ... KIND LED , proving the stigma is gone and ... The overwhelming positive response from customers and their first hand ...
(Date:4/28/2015)... 2015 Jovium®, a brand focused on ... better emotional balance, has begun to increase its market ... scale to enhance their mood and relieve some of ... Jovium® System aims to help patients overcome some of ... through all-natural products that do not cause or carry ...
(Date:4/28/2015)... NV (PRWEB) April 28, 2015 According ... Center for Ethics (June 27, 2014), prescription drugs ... world. Medical Science is becoming increasingly aware of the ... the market, such as chemotherapy drugs to treat cancer, ... that are quickly evolving to become increasingly resistant to ...
(Date:4/28/2015)... Foot and Ankle Specialists of ... Palmer ( Annapolis and Clarksville Divisions ) was ... the Maryland Podiatric Medical Association meeting on April 15, ... in 1992 with a Bachelor of Arts in Life ... intercollegiate soccer, track and cross-country. He then attended the ...
Breaking Medicine News(10 mins):Health News:SuperCloset Reports Surge in KIND LED Grow Light Sales, Saving Indoor Growing Enthusiasts up to 40% on their Power Usage. 2Health News:Jovium® Products Help Customers to Achieve Emotional Balance 2Health News:Trivedi Science™ Announces the Beginning of Their Science Research to Create Highly Effective Pharmaceutical Drugs with Minimal Side Effects 2Health News:Trivedi Science™ Announces the Beginning of Their Science Research to Create Highly Effective Pharmaceutical Drugs with Minimal Side Effects 3Health News:Trivedi Science™ Announces the Beginning of Their Science Research to Create Highly Effective Pharmaceutical Drugs with Minimal Side Effects 4Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Podiatrist Receives Maryland Podiatric Medical Association Outstanding Service Award 2
... , , CUPERTINO, Calif., July ... that Matthew Hogan, Chief Financial Officer, will be presenting at the ... August 5 at 4:00 pm Eastern Time. The conference is ... A webcast of the presentation will be accessible at: ...
... , WASHINGTON, July 28 The ... House of Representatives, goal of expanding health coverage to a ... the Society urges the House to make significant revisions to ... care its first priority and protect patient access to specialists. ...
... FRANKLIN LAKES, N.J., July 28 The Board of Directors ... a quarterly dividend of 33 cents per common share, payable on September ... annual dividend rate is $1.32 per share. , , ... technology company that develops, manufactures and sells medical devices, instrument systems and ...
... , MORRISTOWN, N.J., July 28 Watson Pharmaceuticals, ... and specialty branded pharmaceuticals, today announced a license agreement with ... generic version of Ferrlecit (sodium ferric gluconate complex in sucrose ... anemia in hemodialysis patients receiving supplemental epoetin therapy. , ...
... , , Hoag Hospital recognized ... providing optimal level care to breastfeeding mothers and infants , ... Memorial Hospital Presbyterian announced today its designation as a certified Baby-Friendly ... World Health Organization (WHO) and the United Nations Children,s Fund (UNICEF). ...
... PHILADELPHIA Cancer researchers are turning to mathematical models ... paper in Cancer Research , a journal of ... technique may answer questions about Herceptin resistance. ... Oncology Program at the University of Michigan Comprehensive Cancer ...
Cached Medicine News:Health News:DURECT to Present at the BMO Capital Markets Healthcare Conference 2Health News:SCAI Opposes U.S. House of Representatives Health Reform Bill in Current Form 2Health News:SCAI Opposes U.S. House of Representatives Health Reform Bill in Current Form 3Health News:Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit(R) 2Health News:Hoag Hospital Certified as Baby-Friendly Facility 2Health News:Hoag Hospital Certified as Baby-Friendly Facility 3Health News:Mathematical modeling predicts response to Herceptin 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: